Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 6c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q1 EPS of ($0.91), $0.06 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17.39 million versus the consensus estimate of $9 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Motorola Solutions (MSI) Declares $1.21 Quarterly Dividend; 1% Yield
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates